Registry of Lobbyists
Version 2 of 33 (2007-12-11 to 2008-07-02) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
Amgen Canada Inc.
6755 Mississauga Road Mississauga, ON L5N 7Y2 Canada |
| Telephone number: | 416-643-6817 |
| Fax number: | |
| Responsible officer name and position during the period of this registration: | Daniel Billen, Vice President & General Manager |
| Description of activities: | Scientific affairs; Commercial operations; and administrative activities in biotechnology sector. |
| The client is a subsidiary of the following parent companies: |
Amgen Inc.
One Amgen Center Drive Thousand Oaks, CA United States of America 91320-1799 |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | Paul Moen |
| Position title: | Director, Federal Government Affairs |
| Public offices held: | Yes |
| Name: | Geoff Sprang |
| Position title: | Director, Corporate Affairs |
| Public offices held: | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Finance Canada (FIN), Health Canada (HC), Industry Canada, Patented Medicine Prices Review Board (PMPRB) | ||||||||||||||||||||||||||||||||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Meetings, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||||||||||||||||||||||||||||||
| Subject Matter: Areas of Concern: | Health, Industry, Intellectual Property, Science and Technology, Taxation and Finance | ||||||||||||||||||||||||||||||||||
| Subject Matter: Retrospective: | - Health Canada re: Food and Drug Act, Regulations and Guidance- Health Canada re: Patented Medicines Notice of Compliance (NOC) Regulations- Health Canada re: Progressive Licensing Framework Policy- Health Canada re: Subsequent Entry Biologics Policy- Health Canada re: National Pharmaceutical Strategy- Health Canada re: Canadian Agency for Drugs and Technology in Health, Common Drug Review, Regulatory Approval, Health Canada- Food and Drug Act- Industry Canada re: Patent Act, Regulations and Guidance (including those on Patented Medicines Price Review Board)- Innovation Strategy Industry Canada re: "Mobilizing Science and Technology to Canada's Advantage" | ||||||||||||||||||||||||||||||||||
| Subject Matter: Prospective: | - Health Canada re: Food and Drug Act, Regulations and Guidance- Health Canada re: Patented Medicines Notice of Compliance (NOC) Regulations- Health Canada re: Progressive Licensing Framework Policy- Health Canada re: Subsequent Entry Biologics Policy- Health Canada re: National Pharmaceutical Strategy- Health Canada re: Canadian Agency for Drugs and Technology in Health, Common Drug Review, Regulatory Approval, Health Canada- Food and Drug Act- Industry Canada re: Patent Act, Regulations and Guidance (including those on Patented Medicines Price Review Board)- Innovation Strategy Industry Canada re: "Mobilizing Science and Technology to Canada's Advantage" | ||||||||||||||||||||||||||||||||||
Details Regarding the Identified Subject Matter
|
|||||||||||||||||||||||||||||||||||
This is the responsible officer name as provided in the most recent registration for the corporation or organization.
| Name | From | To |
|---|---|---|
| Amgen Canada Inc. | 2024-04-01 | current |
| Amgen Canada Inc. | 2008-07-02 | 2024-04-01 |
| Responsible Officer Name | From (YYYY-MM-DD) | To (YYYY-MM-DD) |
|---|---|---|
| Ugur Gunaydin | 2022-06-06 | Current |
| Roman Stampfli | 2022-01-17 | 2022-06-06 |
| Brian Heath | 2019-10-14 | 2022-01-17 |
| Francesco Di Marco | 2017-10-26 | 2019-10-14 |
| Helen Jordan | 2014-05-02 | 2017-10-26 |
| Anand Varadan | 2011-09-13 | 2014-05-02 |
| Daniel Billen | 2007-05-16 | 2011-09-13 |
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.